Notable recent abstracts
1 Liao GD, Sellors JW, Sun HK et al.
P16INK4A immunohistochemical staining and predictive value for progression of
cervical intraepithelial neoplasia grade 1: a prospective study in China.
Int J Cancer. 134 (7): 1715-24, 2014.
‘p16 overexpression is strongly associated with grade of CIN and risk of progression to
high-grade CIN in women with low-grade lesions.’
2 de Kok IM, van Rosmalen J, Rozemeijer K et al.
How many cervical cancer cases can potentially be prevented using a more sensitive
screening test at young age?
Int J Cancer. 134 (2): 460-6, 2014.
‘…the majority of the cervical cancer cases at young age would still occur even when
applying a more sensitive test at the younger ages’.
3 Signorelli M, Fruscio R, Ceppi L et al.
The role of pelvic and aortic lymphadenectomy at second look surgery in apparent early
stage ovarian cancer after inadequate surgical staging followed by adjuvant
chemotherapy.
Gynecol Oncol. 132 (2): 312-5, 2014.
‘Our study suggests that systemic aortic and pelvic lymphadenectomy at second look is
not indicated in this subset of women.’
4 Sandadi S, Long K, Andikyan V et al.
Postoperative outcomes among patients undergoing thoracostomy tube placement at
time of diaphragm peritonectomy or resection during primary cytoreductive surgery for
ovarian cancer.
Gynecol Oncol. 132 (2): 299-302, 2014.
‘…intraoperative chest tube placement may be considered to decrease the incidence of
symptomatic effusions and the need for postoperative chest tube placement or
thoracocentesis.’
5 Ko EM, Walter P, Jackson A et al.
Metformin is associated with improved survival in endometrial cancer.
Gynecol Oncol. 132 (2): 438-42, 2014.
‘Metformin use was associated with improved recurrence free survival and overall
survival but not time to recurrence, most likely due to improving all-cause mortality.’
6 Gunderson CC. Dutta S. Fader AN. Maniar KP et al.
Pathologic features associated with resolution of complex atypical hyperplasia and
grade 1 endometrial adenocarcinoma after progestin therapy.
Gynecol Oncol. 132(1): 33-7, 2014.
‘In women with complex atypical hyperplasia or well differentiated endometrioid
adenocarcinoma of the uterus, the overall response rate to progestin therapy was 65%;
pre-treatment estrogen/progesterone receptor status did not predict response to
treatment.’
7 Herzog TJ. Armstrong DK. Brady MF et al.
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology
white paper.
Gynecol Oncol. 132(1):8-17, 2014.
‘OS remains the most objective and accepted endpoint because it is least vulnerable to
bias; however, the feasibility of OS in ovarian cancer is compromised by the requirement
for large trial size, prolonged time-line for final analysis, and potential for unintended
loss of treatment effect from active post-progression therapies.’
8
Leary A. Petrella MC. Pautier P et al.
Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors
with invasive implants.
Gynecol Oncol. 132(1):23-7, 2014.
‘Although numbers are small, the objective responses suggest a possible role for
adjuvant chemotherapy in borderline ovarian tumors with invasive implants.’
9 Yoon A. Park JY. Park JY et al.
Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO
staging system: a multicenter review of 114 cases.
Gynecol Oncol. 132(1):70-5, 2014.
‘Bilateral salpingo-oophorectomy as the primary treatment and cytoreductive resection
of recurrent lesions should be considered for improving survival of patients with
endometrial stromal sarcoma.’